Patents by Inventor Yoon Suk Lee
Yoon Suk Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240262799Abstract: Disclosed are methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, disorder of bile acid homeostasis, or organ fibrosis, which includes administering to a subject a therapeutically effective amount of a pharmaceutical composition containing an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.Type: ApplicationFiled: January 23, 2024Publication date: August 8, 2024Applicant: IL DONG PHARMACEUTICAL CO., LTD.Inventors: Jae-Hoon KANG, Hong-Sub LEE, Yoon-Suk LEE, Jin-Ah JEONG, Sung-Wook KWON, Jeong-Guen KIM, Kyung-Sun KIM, Dong-Keun SONG, Sun-Young PARK, Kyeo-Jin KIM, Ji-Hye CHOI, Hey-Min HWANG
-
Publication number: 20240246961Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: ApplicationFiled: January 23, 2024Publication date: July 25, 2024Inventors: Sung-Ku CHOI, Yoon-Suk LEE, Sung-Wook KWON, Kyung-Sun KIM, Jeong-Geun KIM, Jeong-Ah KIM, An-Na MOON, Sun-Young PARK, Jun-Su BAN, Dong-Keun SONG, Kyu-Sic JANG, Ju-Young JUNG, Soo-Jin LEE
-
Patent number: 12039297Abstract: A code inspection interface providing method according to an embodiment of this disclosure includes providing a graphical user interface (GUI) for performing code inspection, executing an analysis routine on an inspection target code when the inspection target code is selected through the GUI, and providing the result of executing the analysis routine. The analysis routine may include an operation of extracting an abstract syntax tree includes a plurality of nodes from the inspection target code. A code inspection interface providing method is capable of providing an interface that can analyze a code and detect a security vulnerability in real time regardless of the language version of the code and an apparatus for implementing the method.Type: GrantFiled: June 29, 2022Date of Patent: July 16, 2024Assignee: SAMSUNG SDS CO., LTD.Inventors: Hyung Suk Moon, Hee Cheol Park, Yoon Chan Jhi, Jong Hwan Lee
-
Patent number: 11970493Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: GrantFiled: October 4, 2021Date of Patent: April 30, 2024Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Sung-Ku Choi, Yoon-Suk Lee, Sung-Wook Kwon, Kyung-Sun Kim, Jeong-Geun Kim, Jeong-Ah Kim, An-Na Moon, Sun-Young Park, Jun-Su Ban, Dong-Keun Song, Kyu-Sic Jang, Ju-Young Jung, Soo-Jin Lee
-
Publication number: 20240067524Abstract: Sustainable upcycling method of preparing an electrocatalyst, the method including: providing an electrode material obtained from a lithium-ion battery, wherein the electrode material includes LiFePO4@N-doped carbon core-shell particles; contacting the electrode material with an aqueous solution comprising an acid thereby forming the electrocatalyst; and optionally drying the electrocatalyst.Type: ApplicationFiled: August 25, 2023Publication date: February 29, 2024Inventors: Lawrence Yoon Suk LEE, Mengjie LIU
-
Patent number: 11912674Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.Type: GrantFiled: March 4, 2021Date of Patent: February 27, 2024Assignee: IL DONG PHARMACEUTICAL CO., LTD.Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
-
Publication number: 20240041888Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.Type: ApplicationFiled: October 2, 2023Publication date: February 8, 2024Applicant: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Kyung-Sun KIM, Jeong-Ah KIM, An-Na MOON, DONG-Keun SONG, Yoon-Suk LEE, Ju-Young JUNG
-
Patent number: 11806350Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.Type: GrantFiled: November 17, 2021Date of Patent: November 7, 2023Assignee: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Kyung-Sun Kim, Jeong-Ah Kim, An-Na Moon, Dong-Keun Song, Yoon-Suk Lee, Ju-Young Jung
-
Publication number: 20230159534Abstract: The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson’s disease.Type: ApplicationFiled: November 19, 2020Publication date: May 25, 2023Applicant: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Yoon-Suk LEE, Sung-Wook KWON, Kyung-Sun KIM, Jeong-Geun KIM, Jeong-Ah KIM, An-Na MOON, Sun-Young PARK, Jun-Su BAN, Dong-Keun SONG, Ju-Young JUNG, Soo-Jin LEE
-
Publication number: 20220380376Abstract: The present disclosure provides phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase (sGC) via donation of nitrogen oxide (NO) from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of protein kinase G (PKG). The compounds and compositions find use in therapeutic applications including in the treatment of a variety of eye diseases.Type: ApplicationFiled: May 10, 2022Publication date: December 1, 2022Inventors: Yoon-Suk LEE, Sung-Wook KWON, Kyung-Sun KIM, Jeong-Geun KIM, Jeong-Ah KIM, An-Na MOON, Sun-Young PARK, Jun-Su BAN, Dong-Keun SONG, Ju-Young JUNG, Soo-Jin LEE
-
Publication number: 20220152034Abstract: Adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds are disclosed. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson's disease. The compounds and compositions may also find use in various therapeutic applications including the treatment of cancer and in immuno-oncology.Type: ApplicationFiled: November 17, 2021Publication date: May 19, 2022Applicant: ILDONG PHARMACEUTICAL CO., LTD.Inventors: Kyung-Sun KIM, Jeong-Ah KIM, An-Na MOON, Dong-Keun SONG, Yoon-Suk LEE, Ju-Young JUNG
-
Publication number: 20220153746Abstract: The present disclosure provides uses of phosphodiesterase 5 (PDE-5) and/or phosphodiesterase 6 (PDE-6) inhibitor compounds and uses of compositions including said compounds. In some embodiments, said compounds are nitrogen oxide (NO) donating PDE-5 and/or -6 inhibitor compounds that include a nitrogen oxide-containing donor substituent attached to a benzenesulfonamide group. The compounds can provide dual functionality for increasing protein kinase G (PKG) activity by inhibiting PDE-5 and PDE-6, and/or stimulating guanylate cyclase via donation of NO from the donor substituent of the compound. The present disclosure also provides methods of using said compounds and compositions for inhibiting PDE-5 and/or -6 and increasing activity of PKG. The compounds and compositions find use in the treatment of a variety of eye diseases.Type: ApplicationFiled: November 8, 2021Publication date: May 19, 2022Inventors: Yoon-Suk LEE, Kyung-Sun KIM, Jeong-Ah KIM, An-Na MOON, Dong-Keun SONG, Ju-Young JUNG
-
Publication number: 20220106311Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.Type: ApplicationFiled: October 4, 2021Publication date: April 7, 2022Inventors: Sung-Ku Choi, Yoon-Suk Lee, Sung-Wook Kwon, Kyung-Sun Kim, Jeong-Geun Kim, Jeong-Ah Kim, An-Na Moon, Sun-Young Park, Jun-Su Ban, Dong-Keun Song, Kyu-Sic Jang, Ju-Young Jung, Soo-Jin Lee
-
Publication number: 20210188790Abstract: The present invention provides methods for treating or ameliorating metabolic diseases, cholestatic liver diseases, or organ fibrosis, which comprises administering to a subject a therapeutically effective amount of a pharmaceutical composition comprising an isoxazole derivative, a racemate, an enantiomer, or a diastereoisomer thereof, or a pharmaceutically acceptable salt of the derivative, the racemate, the enantiomer, or the diastereoisomer.Type: ApplicationFiled: March 4, 2021Publication date: June 24, 2021Inventors: Jae-Hoon KANG, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
-
Patent number: 10988449Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).Type: GrantFiled: April 12, 2018Date of Patent: April 27, 2021Assignee: IL DONG Pharmaceutical Co., Ltd.Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Jin-Ah Jeong, Sung-Wook Kwon, Jeong-Guen Kim, Kyung-Sun Kim, Dong-Keun Song, Sun-Young Park, Kyeo-Jin Kim, Ji-Hye Choi, Hey-Min Hwang
-
Patent number: 10636167Abstract: A method and device for determining a distance are provided. The method includes determining a first binocular distance between two eyes of a user by using a first image captured through a camera of the device, determining a second binocular distance between the two eyes of the user by using a second image captured through the camera, determining a distance from the camera to the two eyes of the user based on the first binocular distance and the second binocular distance, and providing an image to a display of the device, the image converted according to the distance from the camera to the two eyes of the user.Type: GrantFiled: August 9, 2017Date of Patent: April 28, 2020Assignee: Samsung Electronics Co., Ltd.Inventors: Seok-myong Kang, Yoon-suk Lee, Jong-woo Lee, Jong-gu Jeon
-
Publication number: 20200115349Abstract: The present invention relates to isoxazole derivatives, including pharmaceutical compositions and for the preparation of isoxazole derivatives. And more particularly the present invention provided a pharmaceutical composition of isoxazole derivatives for activation of Farnesoid X receptor (FXR, NR1H4).Type: ApplicationFiled: April 12, 2018Publication date: April 16, 2020Inventors: Jae-Hoon KANG, Hong-Sub LEE, Yoon-Suk LEE, Jin-Ah JEONG, Sung-Wook KWON, Jeong-Guen KIM, Kyung-Sun KIM, Dong-Keun SONG, Sun-Young PARK, Kyeo-Jin KIM, Ji-Hye CHOI, Hey-Min HWANG
-
Patent number: 10302256Abstract: A lighting apparatus including a plurality of frames connected to each other in the lengthwise direction; a connector, which is arranged between the plurality of frames and interconnects the plurality of frames by including a portion inserted into one of the plurality of frames, and including another portion inserted into the other one of the plurality of frames; and a light source arranged on the plurality of frames.Type: GrantFiled: April 18, 2016Date of Patent: May 28, 2019Assignee: Samsung Electronics Co., Ltd.Inventors: Young-kwang Kwon, Joo-hun Han, Bang-won Oh, Du-su Kwon, Hyun-kyung Kim, Yoon-ki Park, Yoon-suk Lee
-
Publication number: 20180137648Abstract: A method and device for determining a distance are provided. The method includes determining a first binocular distance between two eyes of a user by using a first image captured through a camera of the device, determining a second binocular distance between the two eyes of the user by using a second image captured through the camera, determining a distance from the camera to the two eyes of the user based on the first binocular distance and the second binocular distance, and providing an image to a display of the device, the image converted according to the distance from the camera to the two eyes of the user.Type: ApplicationFiled: August 9, 2017Publication date: May 17, 2018Inventors: Seok-myong KANG, Yoon-suk LEE, Jong-woo LEE, Jong-gu JEON
-
Patent number: RE49338Abstract: The present invention relates to phthalazinone derivatives, including pharmaceutical compositions and for the preparation of phthalazinone derivatives. And more particularly the present invention provided a pharmaceutical composition of phthalazinone derivatives for inhibiting activity of the Poly(ADP-riboside) polymerase enzyme.Type: GrantFiled: June 20, 2019Date of Patent: December 20, 2022Assignee: IDIENCE CO., LTD.Inventors: Jae-Hoon Kang, Hong-Sub Lee, Yoon-Suk Lee, Joon-Tae Park, Kyung-Mi An, Jin-Ah Jeong, Kyung-Sun Kim, Jeong-Geun Kim, Chang-Hee Hong, Sun-Young Park, Dong-Keun Song, Yong-Don Yun